Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Central Nervous System Neoplasms 6Glioblastoma 3Astrocytoma 3Gliosarcoma 2Brain Neoplasms 2Spinal Cord Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1

Interventions

Dexamethasone 33Cyclophosphamide 28Melphalan 26Specimen Handling 24Biopsy 24Bortezomib 23Magnetic Resonance Spectroscopy 17Calcium Dobesilate 17fludarabine phosphate 15Lenalidomide 15Filgrastim 15Vincristine 12Prednisone 12Peripheral Blood Stem Cell Transplantation 12sargramostim 9dexamethasone acetate 9dexamethasone 21-phosphate 9carfilzomib 9auricularum 9Doxorubicin 9fludarabine 8Thalidomide 8Interferon-alpha 7Cyclosporine 7Busulfan 7trametinib 6Rituximab 6Etoposide 6ixazomib 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multiple Myeloma × Lomustine × Clear all
NCT00003603 2013-09-20

Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Unknown
660 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡